三氧化二砷在慢性髓细胞白血病中的研究进展

Research progress of arsenic trioxide in chronic myeloid leukemia

早在19世纪,Fowler液,即三氧化二砷（arsenic trioxide,ATO）就被用于慢性髓细胞白血病（chronic myeloid leukemia,CML）的治疗,在化疗药物问世之前,ATO一直是治疗CML的主要药物,单用ATO 2周可使74%的慢性期CML患者获得完全血液学缓解〔1-2〕。由于其独特的作用机制,即使在酪氨酸激酶抑制剂时代,ATO仍可在CML的治疗中发挥独特的作用〔3-4〕。本文就近年来ATO治疗CML的研究进展作一综述。

Arsenic trioxide（ATO）has been confirmed with better clinical efficacy in acute promyelocytic leukemia.In recent years,studies of ATO in chronic myeloid leukemia（CML）have been gradually carried out and found that it could restrain the growth of the CML cell lines and improve the clinical efficacy of CML patients.In addition,more studies found that ATO could influence a variety of biological mechanisms in CML,including the induction of apoptosis,autophagy and stem cell killing.The purpose of this review is to summarize the basic and clinical researches and biological mechanisms of ATO in CML.